MRNA:NSD-Moderna, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 70.24

Change

-0.29 (-0.41)%

Market Cap

USD 27.83B

Volume

3.86M

Average Target Price

USD 83.30 (+18.59%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Moderna, Inc., a clinical stage biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, and cardiovascular diseases. As of February 15, 2019 the company had 11 programs in clinical trials and a total of 20 development candidates in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca, Merck & Co., Vertex Pharmaceuticals, Biomedical Advanced Research and Development Authority, Defense Advanced Research Projects Agency, and Bill & Melinda Gates Foundation; and a research collaboration with Harvard University. Moderna, Inc. also has collaborations with Lonza Ltd. for the manufacture of mRNA-1273, a COVID-19 vaccine; and Catalent for fill-finish manufacturing of its COVID-19 vaccine candidate. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-10-26 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
REGN Regeneron Pharmaceuticals, Inc

+5.93 (+1.02%)

USD61.69B 22.47 17.37
VRTX Vertex Pharmaceuticals Incorpo..

-4.43 (-2.09%)

USD55.11B 26.75 20.98
SGEN Seagen Inc

-1.09 (-0.55%)

USD34.26B N/A N/A
BGNE BeiGene, Ltd

+2.28 (+0.76%)

USD27.09B N/A N/A
ALXN Alexion Pharmaceuticals, Inc

-0.85 (-0.70%)

USD26.65B 32.43 29.34
RPRX Royalty Pharma plc

-0.24 (-0.62%)

USD23.68B 33.93 9.28
GMAB Genmab A/S

-0.70 (-1.96%)

USD22.98B 25.74 2.86
BNTX BioNTech SE

-5.76 (-6.49%)

USD21.12B -99,999.99 N/A
IMMU Immunomedics, Inc

-78.93 (-89.83%)

USD20.31B N/A N/A
INCY Incyte Corporation

+0.75 (+0.84%)

USD19.62B 47.64 35.20

ETFs Containing MRNA

Symbol Name Weight Mer Price(Change) Market Cap
BBH VanEck Vectors Biotech ET.. 0.00 % 0.35 %

-2.44 (-1.53%)

USD0.49B
XBI SPDR S&P Biotech ETF 0.00 % 0.35 %

-1.58 (-1.34%)

USD5.24B
BTEK:LSE iShares Nasdaq US Biotech.. 0.00 % 0.35 %

-0.04 (-0.85%)

USD0.19B
IDNA iShares Genomics Immunolo.. 0.00 % 0.47 %

-0.13 (-0.33%)

USD0.15B
BTEC Principal Healthcare Inno.. 0.00 % 0.42 %

-0.55 (-1.10%)

USD0.10B
RBUS Nationwide Risk-Based U.S.. 0.00 % 0.30 %

-0.44 (-1.31%)

USD0.11B
MXDU Nationwide Maximum Divers.. 0.00 % 0.34 %

-0.50 (-1.45%)

USD0.10B
AIEQ AI Powered Equity ETF 0.00 % 0.87 %

-0.31 (-0.98%)

USD0.10B
VBK Vanguard Small-Cap Growth.. 0.00 % 0.07 %

-4.18 (-1.82%)

USD27.33B
BIB ProShares Ultra Nasdaq Bi.. 0.00 % 0.95 %

-1.37 (-1.94%)

USD0.21B
VB Vanguard Small-Cap Index .. 0.00 % 0.05 %

-3.64 (-2.18%)

USD89.85B
SCHA Schwab U.S. Small-Cap ETF 0.00 % 0.04 %

-1.66 (-2.23%)

USD9.64B
PTH Invesco DWA Healthcare Mo.. 0.00 % 0.60 %

-1.83 (-1.27%)

USD0.67B
IPO Renaissance IPO ETF 0.00 % 0.60 %

-1.17 (-2.15%)

USD0.07B
IBB iShares Nasdaq Biotechnol.. 0.00 % 0.47 %

-1.38 (-1.01%)

USD9.52B
FLAG FLAG-Forensic Accounting .. 0.00 % 1.44 %

N/A

USD4.83M
CNCR Loncar Cancer Immunothera.. 0.00 % 0.79 %

-0.76 (-2.72%)

USD0.04B
BTEE:LSE iShares Nasdaq US Biotech.. 0.00 % 0.35 %

-0.07 (-1.08%)

USD0.19B

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 259.10% 95% A 97% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 259.10% 95% A 97% A+
Trailing 12 Months  
Capital Gain 312.45% 93% A 96% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 312.45% 93% A 96% A
Trailing 5 Years  
Capital Gain 24,120.69% 99% A+ 100% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 24,120.69% 99% A+ 100% A+
Average Annual (5 Year Horizon)  
Capital Gain 782.30% N/A N/A 99% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 782.30% N/A N/A 99% A+
Risk Return Profile  
Volatility (Standard Deviation) 1,059.68% N/A N/A 1% F
Risk Adjusted Return 73.82% N/A N/A 84% B
Market Capitalization 27.83B 99% A+ 97% A+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 9.44 21% F 14% F
Price / Cash Flow Ratio -60.64 95% A 94% A
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -22.75% 86% B 34% F
Return on Invested Capital -40.30% 72% C- 22% F
Return on Assets -12.41% 82% B- 25% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 3.02 59% F 49% F
Short Percent 9.99% 34% F 23% F
Beta 1.21 62% D- 44% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector